Screener
Kyverna Therapeutics, Inc. KYTX Ratios & Valuation
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Returns | ||||||
| Return on equity | -74.5%-24.8pp | -64.7%— | -70.8%— | -61.3%— | -49.7%— | |
| Return on invested capital | -94.5%+5.1pp | -116.4%— | -103.7%— | -98.1%— | -99.6%— | |
| Liquidity | ||||||
| Current ratio | 8.1×+0.7× | 7.8×-0.9× | 5.2×-5.3× | 5.4×-9.5× | 7.4×-9.7× | |
| Leverage | ||||||
| Debt-to-equity | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | |
| Per Share | ||||||
| Book value per share | $3.24-37.6% | $5.25-24.5% | $3.50-50.1% | $4.27-44.8% | $5.18-65.9% | |
| Valuation | ||||||
| Market capitalization | $403.22M+53.4% | $560.3M+247% | $259.47M+23.0% | $137.87M-57.4% | $83.32M-85.9% | |
| Price / book | 2.1×+0.3× | 2.4×+1.8× | 1.7×+1.0× | 0.7×-0.2× | 0.4×-1.3× |
FAQ
- Where do Kyverna Therapeutics, Inc.'s ratios come from?
- Every ratio is computed from Kyverna Therapeutics, Inc.'s SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.